Teis, Albert
Cediel, G.
Amigó, N.
Julve, J.
Aranyó, J.
Andrés-Cordón, J.
Puig-Jové, C.
Castelblanco, E.
Gual-Capllonch, F.
Ferrer-Sistach, E.
Vallejo, N.
Juncà, G.
López-Ayerbe, J.
De Antonio, M.
Domingo, M.
Santiago-Vacas, E.
Codina, P.
Mauricio, D.
Lupón, J.
Alonso, Nuria
Bayes-Genis, A.
Funding for this research was provided by:
Fundació la Marató de TV3 (201602-30-31, 201502)
Ministerio de Economía, Industria y Competitividad, Gobierno de España (PI17-00232, PI17-01362)
Instituto de Salud Carlos III (RED2018-102799-T, PI15-00625)
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CB15/00071)
Ministerio de Educación, Cultura y Deporte (SAF2014-59892)
AdvanceCat (2014-2020)
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CB16/11/00403)
Article History
Received: 29 September 2020
Accepted: 25 January 2021
First Online: 4 February 2021
Competing interests
: N. Amigó is stock owner of Biosfer Teslab and has a patent of the lipoprotein profiling described in the present manuscript. The rest of authors have nothing to disclose. The Funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.